Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 108

1.

Structure-Based Identification of HIV-1 Nucleocapsid Protein Inhibitors Active against Wild-Type and Drug-Resistant HIV-1 Strains.

Mori M, Kovalenko L, Malancona S, Saladini F, De Forni D, Pires M, Humbert N, Real E, Botzanowski T, Cianférani S, Giannini A, Dasso Lang MC, Cugia G, Poddesu B, Lori F, Zazzi M, Harper S, Summa V, Mely Y, Botta M.

ACS Chem Biol. 2018 Jan 19;13(1):253-266. doi: 10.1021/acschembio.7b00907. Epub 2017 Dec 28.

PMID:
29235845
2.

Exploitation of Langerhans cells for in vivo DNA vaccine delivery into the lymph nodes.

Tőke ER, Lőrincz O, Csiszovszki Z, Somogyi E, Felföldi G, Molnár L, Szipőcs R, Kolonics A, Malissen B, Lori F, Trocio J, Bakare N, Horkay F, Romani N, Tripp CH, Stoitzner P, Lisziewicz J.

Gene Ther. 2014 Jun;21(6):566-74. doi: 10.1038/gt.2014.29. Epub 2014 Apr 3.

PMID:
24694539
3.

Safety, tolerability, and immunogenicity of repeated doses of dermavir, a candidate therapeutic HIV vaccine, in HIV-infected patients receiving combination antiretroviral therapy: results of the ACTG 5176 trial.

Rodriguez B, Asmuth DM, Matining RM, Spritzler J, Jacobson JM, Mailliard RB, Li XD, Martinez AI, Tenorio AR, Lori F, Lisziewicz J, Yesmin S, Rinaldo CR, Pollard RB.

J Acquir Immune Defic Syndr. 2013 Dec 1;64(4):351-9. doi: 10.1097/QAI.0b013e3182a99590.

4.

VS411 reduced immune activation and HIV-1 RNA levels in 28 days: randomized proof-of-concept study for antiviral-hyperactivation limiting therapeutics.

Lori F, De Forni D, Katabira E, Baev D, Maserati R, Calarota SA, Cahn P, Testori M, Rakhmanova A, Stevens MR.

PLoS One. 2012;7(10):e47485. doi: 10.1371/journal.pone.0047485. Epub 2012 Oct 19.

5.

Single DermaVir immunization: dose-dependent expansion of precursor/memory T cells against all HIV antigens in HIV-1 infected individuals.

Lisziewicz J, Bakare N, Calarota SA, Bánhegyi D, Szlávik J, Ujhelyi E, Tőke ER, Molnár L, Lisziewicz Z, Autran B, Lori F.

PLoS One. 2012;7(5):e35416. doi: 10.1371/journal.pone.0035416. Epub 2012 May 9.

6.

DermaVir: a plasmid DNA-based nanomedicine therapeutic vaccine for the treatment of HIV/AIDS.

Lori F.

Expert Rev Vaccines. 2011 Oct;10(10):1371-84. doi: 10.1586/erv.11.118.

PMID:
21988301
7.

Amplified antigen-specific immune responses in HIV-1 infected individuals in a double blind DNA immunization and therapy interruption trial.

Gudmundsdotter L, Wahren B, Haller BK, Boberg A, Edbäck U, Bernasconi D, Buttò S, Gaines H, Imami N, Gotch F, Lori F, Lisziewicz J, Sandström E, Hejdeman B.

Vaccine. 2011 Jul 26;29(33):5558-66. doi: 10.1016/j.vaccine.2011.01.064. Epub 2011 Feb 5.

PMID:
21300092
8.

A plasmid DNA immunogen expressing fifteen protein antigens and complex virus-like particles (VLP+) mimicking naturally occurring HIV.

Somogyi E, Xu J, Gudics A, Tóth J, Kovács AL, Lori F, Lisziewicz J.

Vaccine. 2011 Jan 17;29(4):744-53. doi: 10.1016/j.vaccine.2010.11.019. Epub 2010 Nov 23.

PMID:
21109034
9.

Strategies to improve efficacy and safety of a novel class of antiviral hyper-activation-limiting therapeutic agents: the VS411 model in [corrected] HIV/AIDS.

De Forni D, Stevens MR, Lori F.

Br J Pharmacol. 2010 Oct;161(4):830-43. doi: 10.1111/j.1476-5381.2010.00940.x. Erratum in: Br J Pharmacol. 2011 Oct;164(4):1392.

10.

Heritability and demographic analyses in the large isolated population of Val Borbera suggest advantages in mapping complex traits genes.

Traglia M, Sala C, Masciullo C, Cverhova V, Lori F, Pistis G, Bione S, Gasparini P, Ulivi S, Ciullo M, Nutile T, Bosi E, Sirtori M, Mignogna G, Rubinacci A, Buetti I, Camaschella C, Petretto E, Toniolo D.

PLoS One. 2009 Oct 22;4(10):e7554. doi: 10.1371/journal.pone.0007554.

11.

Treating HIV/AIDS by reducing immune system activation: the paradox of immune deficiency and immune hyperactivation.

Lori F.

Curr Opin HIV AIDS. 2008 Mar;3(2):99-103. doi: 10.1097/COH.0b013e3282f525cf.

PMID:
19372949
12.

Unsung hero Robert C. Gallo.

Abbadessa G, Accolla R, Aiuti F, Albini A, Aldovini A, Alfano M, Antonelli G, Bartholomew C, Bentwich Z, Bertazzoni U, Berzofsky JA, Biberfeld P, Boeri E, Buonaguro L, Buonaguro FM, Bukrinsky M, Burny A, Caruso A, Cassol S, Chandra P, Ceccherini-Nelli L, Chieco-Bianchi L, Clerici M, Colombini-Hatch S, de Giuli Morghen C, de Maria A, de Rossi A, Dierich M, Della-Favera R, Dolei A, Douek D, Erfle V, Felber B, Fiorentini S, Franchini G, Gershoni JM, Gotch F, Green P, Greene WC, Hall W, Haseltine W, Jacobson S, Kallings LO, Kalyanaraman VS, Katinger H, Khalili K, Klein G, Klein E, Klotman M, Klotman P, Kotler M, Kurth R, Lafeuillade A, La Placa M, Lewis J, Lillo F, Lisziewicz J, Lomonico A, Lopalco L, Lori F, Lusso P, Macchi B, Malim M, Margolis L, Markham PD, McClure M, Miller N, Mingari MC, Moretta L, Noonan D, O'Brien S, Okamoto T, Pal R, Palese P, Panet A, Pantaleo G, Pavlakis G, Pistello M, Plotkin S, Poli G, Pomerantz R, Radaelli A, Robertguroff M, Roederer M, Sarngadharan MG, Schols D, Secchiero P, Shearer G, Siccardi A, Stevenson M, Svoboda J, Tartaglia J, Torelli G, Tornesello ML, Tschachler E, Vaccarezza M, Vallbracht A, van Lunzen J, Varnier O, Vicenzi E, von Melchner H, Witz I, Zagury D, Zagury JF, Zauli G, Zipeto D.

Science. 2009 Jan 9;323(5911):206-7. doi: 10.1126/science.323.5911.206. No abstract available.

PMID:
19131607
13.

Beneficial effect of TRAIL on HIV burden, without detectable immune consequences.

Shepard BD, De Forni D, McNamara DR, Foli A, Rizza SA, Abraham RS, Knutson K, Wettstein PJ, Lori F, Badley AD.

PLoS One. 2008 Aug 28;3(8):e3096. doi: 10.1371/journal.pone.0003096.

14.

Fas, IL-7, and T cells: live and let die.

Lori F.

Blood. 2008 Aug 15;112(4):930-1. doi: 10.1182/blood-2008-05-156695. No abstract available.

PMID:
18684877
15.

IL-15 as memory T-cell adjuvant for topical HIV-1 DermaVir vaccine.

Calarota SA, Dai A, Trocio JN, Weiner DB, Lori F, Lisziewicz J.

Vaccine. 2008 Sep 19;26(40):5188-95. doi: 10.1016/j.vaccine.2008.03.067. Epub 2008 Apr 14.

16.

HIV-1-specific T cell precursors with high proliferative capacity correlate with low viremia and high CD4 counts in untreated individuals.

Calarota SA, Foli A, Maserati R, Baldanti F, Paolucci S, Young MA, Tsoukas CM, Lisziewicz J, Lori F.

J Immunol. 2008 May 1;180(9):5907-15.

17.

A checkpoint in the cell cycle progression as a therapeutic target to inhibit HIV replication.

Foli A, Maiocchi MA, Lisziewicz J, Lori F.

J Infect Dis. 2007 Nov 1;196(9):1409-15. Epub 2007 Sep 26.

PMID:
17922407
18.

The potential of topical DNA vaccines adjuvanted by cytokines.

Lisziewicz J, Calarota SA, Lori F.

Expert Opin Biol Ther. 2007 Oct;7(10):1563-74. Review.

PMID:
17916048
19.

Nanochemistry-based immunotherapy for HIV-1.

Lori F, Calarota SA, Lisziewicz J.

Curr Med Chem. 2007;14(18):1911-9. Review.

PMID:
17691933
20.

Effects of structured treatment interruptions on metabolic, anthropometric, immunologic, and quality of life outcomes in HIV-positive adults on HAART.

Maserati R, Foli A, Tomasoni L, Sighinolfi L, Maggiolo F, Sacchini D, Di Pietro M, Bertelli D, Tinelli C, Lori F.

Curr HIV Res. 2007 May;5(3):337-43.

PMID:
17504175
21.

HIV-1 prophylactic vaccine comprised of topical DermaVir prime and protein boost elicits cellular immune responses and controls pathogenic R5 SHIV162P3.

Cristillo AD, Lisziewicz J, He L, Lori F, Galmin L, Trocio JN, Unangst T, Whitman L, Hudacik L, Bakare N, Whitney S, Restrepo S, Suschak J, Ferrari MG, Chung HK, Kalyanaraman VS, Markham P, Pal R.

Virology. 2007 Sep 15;366(1):197-211. Epub 2007 May 11.

22.

Induction of HIV-specific memory T-cell responses by topical DermaVir vaccine.

Calarota SA, Weiner DB, Lori F, Lisziewicz J.

Vaccine. 2007 Apr 20;25(16):3070-4. Epub 2007 Jan 22.

PMID:
17292518
23.

Virostatics: a new class of anti-HIV drugs.

Lori F, Foli A, Kelly LM, Lisziewicz J.

Curr Med Chem. 2007;14(2):233-41. Review.

PMID:
17266582
24.

Stopping HAART temporarily in the absence of virus rebound: exploring new HIV treatment options.

Lori F, Foli A, Lisziewicz J.

Curr Opin HIV AIDS. 2007 Jan;2(1):14-20. doi: 10.1097/COH.0b013e328011aad6.

PMID:
19372860
25.

Cytokine-adjuvanted HIV-DNA vaccination strategies.

Lori F, Weiner DB, Calarota SA, Kelly LM, Lisziewicz J.

Springer Semin Immunopathol. 2006 Nov;28(3):231-8. Epub 2006 Oct 20. Review.

PMID:
17053912
26.

CD4+ T cell-mediated presentation of non-infectious HIV-1 virion antigens to HIV-specific CD8+ T cells.

Xu JQ, Lori F, Lisziewicz J.

Chin Med J (Engl). 2006 Oct 5;119(19):1629-38.

PMID:
17042976
27.

Topical DermaVir vaccine targeting dendritic cells.

Lisziewicz J, Kelly L, Lori F.

Curr Drug Deliv. 2006 Jan;3(1):83-8.

PMID:
16472097
28.

Hydroxyurea: overview of clinical data and antiretroviral and immunomodulatory effects.

Lori F, Lisziewicz J.

Antivir Ther. 1999;4 Suppl 3:101-8. Review.

PMID:
16021881
29.

Optimal suppression of HIV replication by low-dose hydroxyurea through the combination of antiviral and cytostatic ('virostatic') mechanisms.

Lori F, Foli A, Groff A, Lova L, Whitman L, Bakare N, Pollard RB, Lisziewicz J.

AIDS. 2005 Jul 22;19(11):1173-81.

PMID:
15990570
30.

Lowering the dose of hydroxyurea minimizes toxicity and maximizes anti-HIV potency.

Lori F, Pollard RB, Whitman L, Bakare N, Blick G, Shalit P, Foli A, Peterson D, Tennenberg A, Schrader S, Rashbaum B, Farthing C, Herman D, Norris D, Greiger P, Frank I, Groff A, Lova L, Asmuth D, Lisziewicz J.

AIDS Res Hum Retroviruses. 2005 Apr;21(4):263-72.

PMID:
15943568
31.

DermaVir, a novel HIV immunisation technology.

Lori F, Trocio J, Bakare N, Kelly LM, Lisziewicz J.

Vaccine. 2005 Mar 18;23(17-18):2030-4.

PMID:
15755566
32.
33.

Hydroxyurea exerts a cytostatic but not immunosuppressive effect on T lymphocytes.

Lova L, Groff A, Ravot E, Comolli G, Xu J, Whitman L, Lewis M, Foli A, Lisziewicz J, Lori F.

AIDS. 2005 Jan 28;19(2):137-44.

PMID:
15668538
34.

DermaVir: a novel topical vaccine for HIV/AIDS.

Lisziewicz J, Trocio J, Whitman L, Varga G, Xu J, Bakare N, Erbacher P, Fox C, Woodward R, Markham P, Arya S, Behr JP, Lori F.

J Invest Dermatol. 2005 Jan;124(1):160-9.

35.

Control of viral rebound through therapeutic immunization with DermaVir.

Lisziewicz J, Trocio J, Xu J, Whitman L, Ryder A, Bakare N, Lewis MG, Wagner W, Pistorio A, Arya S, Lori F.

AIDS. 2005 Jan 3;19(1):35-43.

PMID:
15627031
36.

"Virostatics" as a potential new class of HIV drugs.

Kelly LM, Lisziewicz J, Lori F.

Curr Pharm Des. 2004;10(32):4103-20. Review.

PMID:
15579091
37.

APC-targeted immunization for the treatment of HIV-1.

Lori F, Kelly LM, Lisziewicz J.

Expert Rev Vaccines. 2004 Aug;3(4 Suppl):S189-98. Review.

PMID:
15285717
38.

Safety of hydroxyurea in the treatment of HIV infection.

Lori F, Kelly LM, Foli A, Lisziewicz J.

Expert Opin Drug Saf. 2004 Jul;3(4):279-88. Review.

PMID:
15268646
39.

Immune reconstitution and control of HIV.

Lori F, Maserati R, Lisziewicz J, Minoli L.

HIV Clin Trials. 2004 May-Jun;5(3):170-82. No abstract available.

PMID:
15248142
40.

Strategies to decrease viral load rebound, and prevent loss of CD4 and onset of resistance during structured treatment interruptions.

Foli A, Maserati R, Barasolo G, Castelli F, Tomasoni L, Migliorino M, Maggiolo F, Pan A, Paolucci S, Scudeller L, Tinelli C, D'Aquila R, Lisziewicz J, Lori F.

Antivir Ther. 2004 Feb;9(1):123-32.

PMID:
15040544
41.

T-cell receptor excision circles (TREC) in SHIV 89.6p and SIVmac251 models of HIV-1 infection.

Richardson MW, Sverstiuk AE, Silvera P, Greenhouse J, Lisziewicz J, Lori F, Khalili K, Lewis MG, Rappaport J.

DNA Cell Biol. 2004 Jan;23(1):1-13.

PMID:
14965468
42.

2nd International Symposium on Molecular Diagnostics and Skin Gene Therapy.

Lisziewicz J, Lori F.

Expert Opin Biol Ther. 2003 Jul;3(4):683-7.

PMID:
12831372
43.

Hydroxyurea in the treatment of HIV infection: clinical efficacy and safety concerns.

Lisziewicz J, Foli A, Wainberg M, Lori F.

Drug Saf. 2003;26(9):605-24. Review.

PMID:
12814330
44.

Immunological approaches for HIV therapy.

Lori F, Kelly LM, Lisziewicz J.

Curr Drug Targets Infect Disord. 2003 Jun;3(2):171-8. Review.

PMID:
12769793
45.

Vaccinia assay for the rapid detection of functional HIV-specific CD8+ cytotoxic T lymphocytes.

Xu J, Lori F, Lisziewicz J.

J Immunol Methods. 2003 May 1;276(1-2):45-57.

PMID:
12738358
46.

Therapeutic vaccination for future management of HIV/AIDS.

Lisziewicz J, Bakare N, Lori F.

Vaccine. 2003 Jan 30;21(7-8):620-3. Review.

PMID:
12531329
47.

A cytostatic drug improves control of HIV-1 replication during structured treatment interruptions: a randomized study.

García F, Plana M, Arnedo M, Ortiz GM, Miró JM, Lopalco L, Lori F, Pumarola T, Gallart T, Gatell JM.

AIDS. 2003 Jan 3;17(1):43-51.

PMID:
12478068
48.

Gene therapy approaches to HIV infection.

Lori F, Guallini P, Galluzzi L, Lisziewicz J.

Am J Pharmacogenomics. 2002;2(4):245-52. Review.

PMID:
12421095
49.

Quantification of HIV-specific CD8 T cells by in vitro stimulation with inactivated viral particles.

Xu J, Whitman L, Lori F, Lisziewicz J.

AIDS. 2002 Sep 27;16(14):1849-57.

PMID:
12351944
50.

Supplemental Content

Support Center